SCHEMBL24371397

SCHEMBL24371397

CCOc1cc(C(C)C)ccc1C(C)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.57
TSHR P16473 1/20 0.57
KDM4E B2RXH2 1/20 0.50
BCHE P06276 4/20 0.49
ACHE P22303 4/20 0.49
HIF1A Q16665 1/20 0.48
CA9 Q16790 1/20 0.47
MAPT P10636 4/20 0.46
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TDP1 Q9NUW8 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
CREBBP Q92793 1/20 0.43
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9945944 0.87 TSHR (0.57) CYP3A4TSHRKDM4EBCHEACHE
SCHEMBL1547322 0.86 BCHE (0.48) CYP3A4TSHRKDM4EBCHEACHE
SCHEMBL1259349 0.81 ALDH1A1 (0.46) CYP3A4TSHRKDM4EHIF1ACA9
SCHEMBL2281556 0.80 KDM4E (0.75) CYP3A4TSHRKDM4EHIF1ACA9
SCHEMBL4276935 0.78 TSHR (0.62) CYP3A4TSHRKDM4ECA9MAPT
SCHEMBL24371395 0.78 TSHR (0.49) CYP3A4TSHRKDM4EBCHEACHE
SCHEMBL24413627 0.77 TSHR (0.53) TSHRKDM4EBCHEACHELMNA
SCHEMBL683930 0.77 ALDH1A1 (0.50) TSHRKDM4EBCHEACHEMAPT
SCHEMBL24074069 0.77 TSHR (0.61) CYP3A4TSHRKDM4ECA9MAPT
SCHEMBL20505374 0.77 TSHR (0.61) CYP3A4TSHRKDM4ECA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
WO-2022083703-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR5 CYP3A4 3547/4885TSHR 925/4885KDM4E 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.